Congenital Adrenal Hyperplasia

Journal of Pediatric and Adolescent Gynecology

Volumn 24, Issue 3, 2011, Pages 116-126

  Witchel, Selma Feldman ^a   Azziz, Ricardo ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ambiguous genitalia; Congenital adrenal hyperplasia; Hyperandrogenism; Premature adrenarche; Premature pubarche

Indexed keywords

CYPROTERONE ACETATE; DEXAMETHASONE; FINASTERIDE; FLUDROCORTISONE ACETATE; FLUTAMIDE; HISTRELIN; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; LEUPRORELIN; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; PREDNISONE;

ACNE; ADRENAL CORTEX TUMOR; ADRENAL FUNCTION; ALOPECIA; AMBIGUOUS GENITALIA; ANOVULATION; BONE DENSITY; CONGENITAL ADRENAL HYPERPLASIA; CORTICOTROPIN TEST; DIGITAL RECTAL EXAMINATION; ELECTROLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROIMMUNOASSAY; GENE DELETION; GENETIC SCREENING; HEALTH CARE PERSONNEL; HIRSUTISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIQUID CHROMATOGRAPHY; LOSS OF FUNCTION MUTATION; LOW LEVEL LASER THERAPY; MALE TYPE ALOPECIA; MENSTRUAL IRREGULARITY; MISSENSE MUTATION; MOLECULAR GENETICS; NEWBORN SCREENING; OBESITY; OLIGOMENORRHEA; PATHOPHYSIOLOGY; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOIMMUNOASSAY; RECURRENCE RISK; REPRODUCTION; SECONDARY AMENORRHEA; SHORT SURVEY; SOCIAL PSYCHOLOGY; TANDEM MASS SPECTROMETRY; VIRILIZATION;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; CHILD; FEMALE; HUMANS; INFANT, NEWBORN; INFERTILITY, FEMALE; NEONATAL SCREENING;

EID: 79956131423     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2010.10.001     Document Type: Short Survey

References (106)

1. De Crecchio L. Sopra un caso di apparenze virili in una donna. Morgagni 1865, 7:154.
2. Decourt M.J., Jayle M.F., Baulieu E. Virilisme cliniquement tardif avec excretion de pregnanetriol et insuffisance de la production du cortisol. Ann Endocrinol (Paris) 1957, 18:416.
3. Demirci C., Witchel S.F. Congenital adrenal hyperplasia. Dermatol Ther 2008, 21:340.
4. Speiser P.W., Dupont B., Rubinstein P., et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985, 37:650.
5. Pang S., Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993, 2:105.
6. Therrell B.L., Berenbaum S.A., Manter-Kapanke V., et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998, 101:583.
7. Speiser P.W., White P.C. Congenital adrenal hyperplasia. N Engl J Med 2003, 349:776.
8. Speiser P.W., Dupont J., Zhu D., et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992, 90:584.
9. Wedell A., Ritzén E.M., Haglund-Stengler B., et al. Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. Proc Natl Acad Sci U S A 1992, 89:7232.
10. Jaaskelainen J., Levo A., Voutilainen R., et al. Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 1997, 82:3293.
11. Tardy V., Menassa R., Sulmont V., et al. Phenotype-genotype correlations of 13 rare CYP21A2 mutations detected in 46 patients affected with 21-hydroxylase deficiency and one carrier. J Clin Endocrinol Metab 2010, 95:1288.
12. Auchus R.J. Management of the adult with congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2010, 614107. Epub 2010 May 30.
13. Ghayee H.K., Auchus R.J. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord 2007, 8:289.
14. Auchus R.J. Non-traditional metabolic pathways of adrenal steroid. Rev Endocr Metab Disord 2009, 10:27.
15. Asby D.J., Arlt W., Hanley N.A. The adrenal cortex and sexual differentiation during early human development. Rev Endocr Metab Disord 2009, 10:43.
16. Azziz R., Slayden S.M. The 21-hydroxylase-deficient adrenal hyperplasias: more than ACTH oversecretion. J Soc Gynecol Investig 1996, 3:297.
17. Sánchez L.A., Morán C., Reyna R., et al. Adrenal progestogen and androgen production in 21 hydroxylase deficient non-classic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation. Fertil Steril 2002, 77:750.
18. Knorr D., Bidlingmaier F., Höller W., et al. Is heterozygosity for the steroid 21-hydroxylase deficiency responsible for hirsutism, premature pubarche, early puberty, and precocious puberty in children?. Acta Endocrinol Suppl (Copenh) 1986, 279:284.
19. Witchel S.F., Lee P.A., Suda-Hartman M., et al. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med 1997, 62:151.
20. Félix-López X., Riba L., Ordóñez-Sánchez M.L., et al. Steroid 21-hydroxylase (P450c21) naturally occurring mutants I172N, V281L and I236n/V237E/M239K exert a dominant negative effect on enzymatic activity when co-expressed with the wild-type protein. J Pediatr Endocrinol Metab 2003, 16:1017.
21. Huerta R., Dewailly D., Decanter C., et al. Adrenocortical hyper-responsivity to ACTH: A mechanism favoring the normal production of cortisol in 21-hydroxylase deficient non-classic adrenal hyperplasia. Fertil Steril 2000, 74:329.
22. Moreira A.C., Elias L.L. Pituitary-adrenal responses to corticotropin-releasing hormone in different degrees of adrenal 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992, 74:198.
23. Levin J.H., Carmina E., Lobo R.A. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?. Fertil Steril 1991, 56:635.
24. Carmina E., Lobo R.A. Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Fertil Steril 1994, 62:738.
25. Blank S.K., McCartney C.R., Helm K.D., et al. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med 2007, 25:352.
26. Barnes R.B., Rosenfield R.L., Ehrmann D.A., et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994, 79:1328.
27. Abbott D.H., Barnett D.K., Bruns C.M., et al. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?. Hum Reprod Update 2005, 11:357.
28. Armengaud J.B., Charkaluk M.L., Trivin C., et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab 2009, 94:2835.
29. Moran C., Azziz R., Carmina E., et al. 21-hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000, 183:1468.
30. Moran C., Azziz R., Weintrob N., et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006, 91:3451.
31. Bidet M., Bellanné-Chantelot C., Galand-Portier M.B., et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009, 94:1570.
32. Wasniewska M., Raiola G., Galati M.C., et al. Non-classical 21-hydroxylase deficiency in boys with prepubertal or pubertal gynecomastia. Eur J Pediatr 2008, 167:1083.
33. Nigawara T., Kageyama K., Sakihara S., et al. A male case of nonclassical 21-hydroxylase deficiency first manifested in his sixties with adrenocortical incidentaloma. Endocr J 2008, 55:291.
34. O'Driscoll J.B., Anderson D.C. Untreated congenital adrenal hyperplasia presenting with severe androgenic alopecia. J R Soc Med 1993, 86:229.
35. Hatch R., Rosenfield R.L., Kim M.H., et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981, 140:815.
36. Azziz R., Dewailly D., Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994, 78:810.
37. Bidet M., Bellanné-Chantelot C., Galand-Portier M.-B., et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010, 95:1182.
38. Feldman S., Billaud L., Thalabard J.C., et al. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992, 74:635.
39. Stikkelbroeck N.M., Sweep C.G., Braat D.D., et al. Monitoring of menstrual cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency. Fertil Steril 2003, 80:1030.
40. Casteràs A., De Silva P., Rumsby G., et al. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 2009, 70:833.
41. Boyle M.E., Smith S., Liao L.M. Adult genital surgery for intersex: a solution to what problem?. J Health Psychol 2005, 10:573.
42. May B., Boyle M., Grant D. A comparative study of sexual experiences: women with diabetes and women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Health Psychol 1996, 1:479.
43. Gastaud F., Bouvattier C., Duranteau L., et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007, 92:1391.
44. Nordenskjöld A., Holmdahl G., Frisén L., et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008, 93:380.
45. Escobar-Morreale H.F., Sanchón R., San Millán J.L. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008, 93:527.
46. Azziz R., Hincapie L.A., Knochenhauer E.S., et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999, 72:915.
47. Dewailly D., Vantyghem-Haudiquet M.C., Sainsard C., et al. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency. J Clin Endocrinol Metab 1986, 63:418.
48. Pall M., Azziz R., Beires J., et al. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril 2010, 94:684.
49. White P.C. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2009, 5:490.
50. Varness T.S., Allen D.B., Hoffman G.L. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls. J Pediatr 2005, 147:493.
51. Witchel S.F., Nayak S., Suda-Hartman M., et al. Newborn screening for 21-hydroxylase deficiency: results of CYP21 molecular genetic analysis. J Pediatr 1997, 131:328.
52. Soldin S.J., Soldin O.P. Steroid hormone analysis by tandem mass spectrometry. Clin Chem 2009, 55:1061.
53. Janzen N., Peter M., Sander S., et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2007, 92:2581.
54. Kleinle S., Lang R., Fischer G.F., et al. Duplications of the functional CYP21A2 gene are primarily restricted to Q318X alleles: evidence for a founder effect. J Clin Endocrinol Metab 2009, 94:3954.
55. Zeng X., Witchel S.F., Dobrowolski S.F., et al. Detection and assignm ent of CYP21 mutations using peptide mass signature genotyping. Mol Genet Metab 2004, 82:38.
56. Merke D.P. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2008, 93:653.
57. Clayton P.E., Miller W.L., Oberfield S.E., et al. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002, 58:188.
58. Fanta M., Hill M., Belácek J., et al. Comparison of corticoid substitution versus combined oral contraception administration in the treatment of non-classic adrenal hyperplasia: a prospective study. Gynecol Endocrinol 2009, 25:398.
59. Spritzer P., Billaud L., Thalabard J.C., et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1990, 70:642.
60. Azziz R., Koulianos G. Adrenal androgens and reproductive aging in females. Sem Reprod Endo 1991, 9:249.
61. Schaeffer T.L., Tryggestad J.B., Mallappa A., et al. An evidence-based model of multidisciplinary care for patients and families affected by classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Int J Pediatr Endocrinol 2010, 92439. [Epub: 2010 Mar 18].
62. Lee P.A., Witchel S.F. Genital surgery among females with congenital adrenal hyperplasia: changes over the past five decades. J Pediatr Endocrinol Metab 2002, 15:1473.
63. Pescovitz O.H., Comite F., Cassorla F., et al. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 1984, 58:857.
64. Mazziotti G., Angeli A., Bilezikian J.P., et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006, 17:144.
65. Leonard M.B. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007, 119(Suppl 2):S166.
66. Chakhtoura Z., Bachelot A., Samara-Boustani D., et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2008, 158:879.
67. Falhammar H., Filipsson H., Holmdahl G., et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:4643.
68. Bachelot A., Chakthoura Z., Rouxel A., et al. Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008, 69:203.
69. Merke D.P., Chrousos G.P., Eisenhofer G., et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000, 343:1362.
70. Sullivan J.G., Gohel M., Kinder R.B. Ectopic adrenocortical tissue found at groin exploration in children: incidence in relation to diagnosis, age and sex. BJU Int 2005, 95:407.
71. Claahsen-van der Grinten H.L., Otten B.J., Stikkelbroeck M.M., et al. Testicular adrenal rest tumours in congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009, 23:209.
72. Falhammar H., Thorén M. An 88-year-old woman diagnosed with adrenal tumor and congenital adrenal hyperplasia: connection or coincidence?. J Endocrinol Invest 2005, 28:449.
73. Nagasaka S., Kubota K., Motegi T., et al. A case of silent 21-hydroxylase deficiency with persistent adrenal insufficiency after removal of an adrenal incidentaloma. Clin Endocrinol (Oxf) 1996, 44:111.
74. Murakami C., Ishibashi M., Kondo M., et al. Adrenal myelolipoma associated with congenital adrenal 21-hydroxylase deficiency. Intern Med 1992, 31:803.
75. Ogilvie C.M., Crouch N.S., Rumsby G., et al. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol (Oxf) 2006, 64:2.
76. Schalkwijk J., Zweers M.C., Steijlen P.M., et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 2001, 345:1167.
77. Koppens P.F., Hoogenboezem T., Degenhart H.J. Carriership of a defective tenascin-X gene in steroid 21-hydroxylase deficiency patients: TNXB -TNXA hybrids in apparent large-scale gene conversions. Hum Mol Genet 2002, 11:2581.
78. Chen W., Kim M.S., Shanbhag S., et al. The phenotypic spectrum of contiguous deletion of CYP21A2 and tenascin XB: quadricuspid aortic valve and other midline defects. Am J Med Genet A 2009, 149A. 2803.
79. Speiser P.W., Serrat J., New M.I., et al. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992, 75:1421.
80. Bergman R.N., Ider Y.Z., Bowden C.R., et al. Quantitative estimation of insulin sensitivity. Am J Physiol 1979, 236:E667.
81. Sartorato P., Zulian E., Benedini S., et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:1015.
82. Falhammar H., Filipsson H., Holmdahl G., et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:110.
83. Dereli D., Ozgen G., Buyukkececi F., et al. Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab 2003, 88:2263.
84. Meyer-Bahlburg H.F., Dolezal C., Baker S.W., et al. Prenatal androgenization affects gender-related behavior but not gender identity in 5-12-year old girls with congenital adrenal hyperplasia. Arch Sex Behav 2004, 33:97.
85. Berenbaum S.A., Bailey J.M. Effects on gender identity of prenatal androgens and genital appearance: evidence from girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003, 88:1102.
86. Meyer-Bahlburg H.F.L., Dolezal C., et al. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008, 37:85.
87. Jääskeläinen J., Hippeläinen M., Kiekara O., et al. Child rate, pregnancy outcome and ovarian function in females with classical 21-hydroxylase deficiency. Acta Obstet Gynecol Scand 2000, 79:687.
88. David M., Forest M.G. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 1984, 105:799.
89. New M.I., Carlson A., Obeid J., et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001, 86:5651.
90. Pang S., Clark A.T., Freeman L.C., et al. Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992, 75:249.
91. Speiser P.W., Azziz R., Baskin L.S., et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine clinical practice guideline. J Clin Endocrinol Metab 2010, 95:4133.
92. Miller W.L. Dexamethasone treatment of congenital adrenal hyperplasia in utero: an experimental therapy of unproven safety. J Urol 1999, 162:537.
93. Allen S., Gregory J. The transition from children's to adult diabetes services: understanding the 'problem'. Diabetic Medicine 2009, 26:162.
94. Schechter M.S., Margolis P. Improving subspecialty healthcare: lessons from cystic fibrosis. J Pediatr 2005, 147:295.
95. McPherson M., Thaniel L., Minniti C.P. Transition of patients with sickle cell disease from pediatric to adult care: Assessing patient readiness. Pediatr Blood Cancer 2009, 52:838.
96. Tuchman L.K., Slap G.B., Britto M.T. Transition to adult care: experiences and expectations of adolescents with a chronic illness. Child Care Health Dev 2008, 34:557.
97. Kruse B., Riepe F.G., Krone N., et al. Congenital adrenal hyperplasia - how to improve the transition from adolescence to adult life. Exp Clin Endocrinol Diabetes 2004, 112:343.
98. Conway G.S. Congenital adrenal hyperplasia: adolescence and transition. Horm Res 2007, 68(Suppl 5):155.
99. Grosse S.D., Schechter M.S., Kulkarni R., et al. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics 2009, 123:407.
100. Rosen D. Between two worlds: bridging the cultures of child health and adult medicine. J Adolesc Health 1995, 17:10.
101. Kieckhefer G.M., Trahms C.M. Supporting development of children with chronic conditions: from compliance toward shared management. Pediatric Nursing 2000, 26:354.
102. McDonagh J.E., Kaufman M. The challenging adolescent. Rheumatology 2009, 48:872.
103. Giedd J.N. The teen brain: insights from neuroimaging. J Adolesc Health 2008, 42:335.
104. Kelly A.M., Kratz B., Bielski M., et al. Implementing transitions for youth with complex chronic conditions using the medical home model. Pediatrics 2002, 110(6 Pt 2):1322.
105. Witchel S.F. The medical home concept and congenital adrenal hyperplasia: a comfortable habitat!. Int J Pediatr Endocrinol 2010, 2010:561526. Epub 2010 Jun 8.
106. Auchus RJ, Witchel SF, White PC, et al: Development of Comprehensive Care Centers for Management of Patients with Congenital Adrenal Hyperplasia. Poster Presentation [P3-723], Endocrine Society Annual Meeting, June 2010.